1. Home
  2. DNLI vs SYBT Comparison

DNLI vs SYBT Comparison

Compare DNLI & SYBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DNLI
  • SYBT
  • Stock Information
  • Founded
  • DNLI 2013
  • SYBT 1904
  • Country
  • DNLI United States
  • SYBT United States
  • Employees
  • DNLI N/A
  • SYBT N/A
  • Industry
  • DNLI Biotechnology: Biological Products (No Diagnostic Substances)
  • SYBT Major Banks
  • Sector
  • DNLI Health Care
  • SYBT Finance
  • Exchange
  • DNLI Nasdaq
  • SYBT Nasdaq
  • Market Cap
  • DNLI 2.1B
  • SYBT 2.3B
  • IPO Year
  • DNLI 2017
  • SYBT N/A
  • Fundamental
  • Price
  • DNLI $15.43
  • SYBT $79.36
  • Analyst Decision
  • DNLI Strong Buy
  • SYBT Hold
  • Analyst Count
  • DNLI 15
  • SYBT 3
  • Target Price
  • DNLI $33.62
  • SYBT $83.67
  • AVG Volume (30 Days)
  • DNLI 2.0M
  • SYBT 91.4K
  • Earning Date
  • DNLI 11-05-2025
  • SYBT 10-22-2025
  • Dividend Yield
  • DNLI N/A
  • SYBT 1.56%
  • EPS Growth
  • DNLI N/A
  • SYBT 22.18
  • EPS
  • DNLI N/A
  • SYBT 4.35
  • Revenue
  • DNLI N/A
  • SYBT $364,546,000.00
  • Revenue This Year
  • DNLI N/A
  • SYBT $16.83
  • Revenue Next Year
  • DNLI $802.87
  • SYBT $5.12
  • P/E Ratio
  • DNLI N/A
  • SYBT $18.26
  • Revenue Growth
  • DNLI N/A
  • SYBT 11.32
  • 52 Week Low
  • DNLI $10.57
  • SYBT $56.35
  • 52 Week High
  • DNLI $33.33
  • SYBT $83.83
  • Technical
  • Relative Strength Index (RSI)
  • DNLI 56.61
  • SYBT 52.74
  • Support Level
  • DNLI $14.52
  • SYBT $78.75
  • Resistance Level
  • DNLI $16.20
  • SYBT $83.83
  • Average True Range (ATR)
  • DNLI 0.70
  • SYBT 2.00
  • MACD
  • DNLI -0.01
  • SYBT 0.13
  • Stochastic Oscillator
  • DNLI 62.44
  • SYBT 53.39

About DNLI Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

About SYBT Stock Yards Bancorp Inc.

Stock Yards Bancorp Inc operates as a bank. The bank has two reportable operating segments namely Commercial Banking and Wealth Management and Trust. Its services include loan and deposit services, cash management services, securities brokerage activities, mortgage origination, and others. It generates the majority of its revenue from the Commercial Banking segment.

Share on Social Networks: